• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用固定阈值而非相对阈值方法确定总代谢肿瘤体积的基于正电子发射断层扫描的风险建模的支持数据。

Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determination.

作者信息

Schmitz Christine, Hüttmann Andreas, Müller Stefan P, Hanoun Maher, Boellaard Ronald, Brinkmann Marcus, Jöckel Karl-Heinz, Dührsen Ulrich, Rekowski Jan

机构信息

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

出版信息

Data Brief. 2019 Dec 12;28:104976. doi: 10.1016/j.dib.2019.104976. eCollection 2020 Feb.

DOI:10.1016/j.dib.2019.104976
PMID:31890813
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6931116/
Abstract

Total metabolic tumor volume (TMTV) was measured in 510 patients with DLBCL participating in the PETAL trial. The present data provide information about the prognostic impact of total metabolic tumor volume using the fixed standardized uptake value (SUV) instead of the relative SUV thresholding method. A Bland-Altman plot was created to compare both methods. For TMTV assessed by the SUV method a Cox regression was applied to determine its effect on time to progression, progression-free survival, and overall survival. Kaplan-Meier curves and corresponding hazard ratios were used to estimate the effect of TMTV alone or in combination with interim positron emission tomography response on patients' survival. The data relate to the research article entitled "Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: post-hoc analysis from the PETAL trial" [1].

摘要

在参与PETAL试验的510例弥漫性大B细胞淋巴瘤(DLBCL)患者中测量了总代谢肿瘤体积(TMTV)。本数据提供了关于使用固定标准化摄取值(SUV)而非相对SUV阈值化方法的总代谢肿瘤体积的预后影响的信息。创建了Bland-Altman图以比较这两种方法。对于通过SUV方法评估的TMTV,应用Cox回归来确定其对进展时间、无进展生存期和总生存期的影响。使用Kaplan-Meier曲线和相应的风险比来估计TMTV单独或与中期正电子发射断层扫描反应相结合对患者生存的影响。这些数据与题为“基于正电子发射断层扫描的弥漫性大B细胞淋巴瘤动态风险评估:PETAL试验的事后分析”的研究文章相关[1]。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e89/6931116/7afb8efb8376/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e89/6931116/ae425cf6522d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e89/6931116/7afb8efb8376/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e89/6931116/ae425cf6522d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4e89/6931116/7afb8efb8376/gr2.jpg

相似文献

1
Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determination.使用固定阈值而非相对阈值方法确定总代谢肿瘤体积的基于正电子发射断层扫描的风险建模的支持数据。
Data Brief. 2019 Dec 12;28:104976. doi: 10.1016/j.dib.2019.104976. eCollection 2020 Feb.
2
Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.基于正电子发射断层扫描的弥漫性大 B 细胞淋巴瘤动态风险评估:来自 PETAL 试验的事后分析。
Eur J Cancer. 2020 Jan;124:25-36. doi: 10.1016/j.ejca.2019.09.027. Epub 2019 Nov 9.
3
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.基于基线和中期 PET 的外周 T 细胞淋巴瘤预后预测:PETAL 试验的亚组分析。
Hematol Oncol. 2020 Aug;38(3):244-256. doi: 10.1002/hon.2697. Epub 2020 Feb 18.
4
Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma.使用固定或不同自适应阈值方法测量的基线总代谢肿瘤体积对外周T细胞淋巴瘤预后的预测能力相同。
J Nucl Med. 2017 Feb;58(2):276-281. doi: 10.2967/jnumed.116.180406. Epub 2016 Oct 6.
5
Prognostic value of metabolic tumour volume on baseline F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.基线 F-FDG PET/CT 代谢肿瘤体积对弥漫性大 B 细胞淋巴瘤患者 NCCN-IPI 的预后价值:对高危 NCCN-IPI 组的进一步分层。
Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1417-1427. doi: 10.1007/s00259-019-04309-4. Epub 2019 Apr 2.
6
Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.18F-FDG PET/CT 测量的肿瘤体积表面积比估计的肿瘤碎裂是弥漫性大 B 细胞淋巴瘤的独立预后因素。
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1672-1679. doi: 10.1007/s00259-018-4041-0. Epub 2018 Apr 28.
7
Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.弥漫性大 B 细胞淋巴瘤患者的分子谱和 FDG-PET/CT 总代谢肿瘤体积改善了诊断时的风险分类。
Clin Cancer Res. 2016 Aug 1;22(15):3801-9. doi: 10.1158/1078-0432.CCR-15-2825. Epub 2016 Mar 2.
8
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.基线代谢肿瘤体积可预测高肿瘤负荷滤泡性淋巴瘤的预后:三项多中心研究的汇总分析
J Clin Oncol. 2016 Oct 20;34(30):3618-3626. doi: 10.1200/JCO.2016.66.9440. Epub 2016 Sep 30.
9
Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.基线 FDG PET/CT 总代谢肿瘤体积与基因表达谱联合具有弥漫性大 B 细胞淋巴瘤患者强有力的预测价值。
Eur J Nucl Med Mol Imaging. 2018 May;45(5):680-688. doi: 10.1007/s00259-017-3907-x. Epub 2018 Jan 17.
10
Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.基线代谢肿瘤体积和总病变糖酵解对淋巴瘤患者的预后价值:一项荟萃分析。
PLoS One. 2019 Jan 9;14(1):e0210224. doi: 10.1371/journal.pone.0210224. eCollection 2019.

引用本文的文献

1
F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study.氟代脱氧葡萄糖正电子发射断层扫描(FDG PET)可提高弥漫性大 B 细胞淋巴瘤反应的基线临床预测因素:HOVON-84 研究。
J Nucl Med. 2022 Jul;63(7):1001-1007. doi: 10.2967/jnumed.121.262205. Epub 2021 Oct 21.

本文引用的文献

1
Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.基于正电子发射断层扫描的弥漫性大 B 细胞淋巴瘤动态风险评估:来自 PETAL 试验的事后分析。
Eur J Cancer. 2020 Jan;124:25-36. doi: 10.1016/j.ejca.2019.09.027. Epub 2019 Nov 9.
2
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.正电子发射断层扫描引导治疗侵袭性非霍奇金淋巴瘤(PETAL):一项多中心、随机 III 期试验。
J Clin Oncol. 2018 Jul 10;36(20):2024-2034. doi: 10.1200/JCO.2017.76.8093. Epub 2018 May 11.
3
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.
利妥昔单抗联合化疗改善成人伯基特淋巴瘤/白血病的预后:一项大型前瞻性多中心试验报告
Blood. 2014 Dec 18;124(26):3870-9. doi: 10.1182/blood-2014-03-563627. Epub 2014 Oct 30.
4
Statistical methods for assessing agreement between two methods of clinical measurement.评估两种临床测量方法之间一致性的统计方法。
Lancet. 1986 Feb 8;1(8476):307-10.